INTRODUCTION {#s1}
============

The early B-cell factor 3 (EBF3) is a member of the Collier/Olf/EBF (COE) family of transcription factors that have a number of crucial developmental roles ([@BLACKBURNMCS001743C8]). Recently, EBF3 was implicated in a novel neurodevelopmental disorder characterized by intellectual disability with or without central nervous system (CNS) malformations, speech delay, hypotonia, ataxia, facial dysmorphisms, and urogenital anomalies ([@BLACKBURNMCS001743C3]; [@BLACKBURNMCS001743C19]; [@BLACKBURNMCS001743C35]). Three concurrent reports describing a total of 21 patients found several de novo heterozygous missense, nonsense, splice site, and small insertions and deletions involving *EBF3* ([@BLACKBURNMCS001743C3]; [@BLACKBURNMCS001743C19]; [@BLACKBURNMCS001743C35]). Interestingly, all of the missense variants that were identified fell within the highly conserved DNA binding domain (DBD) of EBF3; four had de novo missense variants within a single codon resulting in mutation of the p.Arg163 residue ([@BLACKBURNMCS001743C3]; [@BLACKBURNMCS001743C35]). This residue falls within the "zinc knuckle" motif, is conserved across human EBF paralogs (EBF1-4), and has a crucial role in coordinating DNA binding ([@BLACKBURNMCS001743C17]; [@BLACKBURNMCS001743C10]). Functional analysis of EBF1 p.Arg163Ala showed loss of DNA binding ([@BLACKBURNMCS001743C36]). Functional studies of *EBF3* variants affecting p.Arg163 have confirmed the essential role of this residue ([@BLACKBURNMCS001743C3]; [@BLACKBURNMCS001743C35]). The EBF3 Arg163 codon falls within a CpG dinucleotide island, which could explain why it likely represents a mutation hotspot for this novel disorder ([@BLACKBURNMCS001743C3]). EBF3 binds to DNA as a homodimer but can also heterodimerize with other EBF family members to transactivate target genes ([@BLACKBURNMCS001743C15]). Studies of mutant/wild-type (wt) EBF3 heterodimers show that amino acid substitutions at critical residues could exert a dominant-negative effect, thereby reducing DNA binding and subsequent transcriptional activation ([@BLACKBURNMCS001743C35]). In this report, we describe another patient with a novel heterozygous c.487C\>T (p.(Arg163Trp)) variant in *EBF3* who has significant clinical overlap with other previously described patients. We compare the clinical manifestations of our patient with those of previously reported individuals and also provide structural evidence supporting pathogenicity of the novel c.487C\>T (p.(Arg163Trp)) variant found in this case.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The proband was the product of an uncomplicated pregnancy, delivered at term to a G3P2, 31-yr-old mother and 34-yr-old father. She was noted at birth to have a markedly distended abdomen and was not voiding appropriately. A blind-end dimple was noted at the expected location of urethra and catheterization could not be performed. A percutaneous suprapubic cystoscopy was performed and vaginoscopy demonstrated a normal vagina and cervix with a bicornuate uterus. Urethral meatal stenosis was noted and the urethra was subsequently dilated. The suprapubic tube was removed but she had failed voiding trials, prompting vesicostomy and a diagnosis of atonic bladder. During her evaluation at ∼2 yr of age, she had generalized hypotonia with global developmental delay; she sat independently at 1 yr, was not yet walking at 2 yr, and had a two- to three-word vocabulary. There was no evidence of ataxia or dystonia; deep tendon reflexes were reported decreased throughout. She had bilateral esotropia, short stature with height less than the second percentile, and weight and head circumference around the 25th percentile for age. On exam, she was grossly nondysmorphic, with downturned mouth corners, mild retrognathia, a low posterior hairline, and mild pectus excavatum ([Fig. 1](#BLACKBURNMCS001743F1){ref-type="fig"}). She had normal evaluations that included brain and total spine magnetic resonance imaging (MRI), electromyography (EMG), chromosomal microarray, and comprehensive biochemical metabolic testing. There were no other family members with a similar constellation of findings; however, her mother and maternal grandmother were reported to have strabismus. The proband has two older maternal half-siblings including a sister with a history of attention-deficit/hyperactivity disorder (ADHD) and a brother with ADHD and history of speech delay.

![Patient photographs showing front and side views. The proband was noted to have mild dysmorphic features including bilateral esotropia, retrognathia, downturned corners of the mouth, and a low posterior hairline.](BlackburnMCS001743_F1){#BLACKBURNMCS001743F1}

Genomic Analyses {#s2b}
----------------

To identify variants of interest, whole-exome sequencing was performed on genomic DNA extracted from samples submitted from the proband, biological mother, and biological father; 97% of the exome-capture region was covered at a read depth of 20× or greater. A de novo variant (c.487C\>T, p.(Arg163Trp)) was identified in *EBF3*, which was considered a gene of uncertain significance at the time of analysis ([Table 1](#BLACKBURNMCS001743TB1){ref-type="table"}). This variant was reported due to *EBF3* being implicated as part of the critical region in the 10q26 microdeletion syndrome, which has features overlapping the clinical phenotype of the proband ([@BLACKBURNMCS001743C9]). In silico analyses predicted that this alteration was deleterious, probably damaging, and disease-causing by SIFT (Sorting Intolerant from Tolerant), PolyPhen-2, and MutationTaster2, respectively ([@BLACKBURNMCS001743C24]; [@BLACKBURNMCS001743C1]; [@BLACKBURNMCS001743C34]). This variant has not been reported in the literature or in publically available databases including the Exome Aggregation Consortium (ExAC) and the Genome Aggregation Database (gnomAD) ([@BLACKBURNMCS001743C25]). *EBF3* is highly intolerant to both missense and loss-of-function variation, and the residue mutated in our patient is conserved across species and paralogs ([Fig. 2](#BLACKBURNMCS001743F2){ref-type="fig"}). Targeted Sanger sequencing (forward 5′-ACAACAAATGGTGCAATGCACA-3′, reverse 5′-AAAATACAAGTCGGGCATAAAAGGG-3′) was used to confirm the variant in the proband and absence of the alteration in parental samples.

![Schematic diagram of EBF3 (NP_001005463.1) protein structure. Numbering corresponds to amino acids.](BlackburnMCS001743_F2){#BLACKBURNMCS001743F2}

###### 

Variant Information

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Position (hg19/GRCh37)   Type       Gene     HGVS cDNA         HGVS protein      Zygosity   Inheritance   SIFT/PolyPhen-2/MutationTaster2                 ExAC/gnomAD allele frequency
  ------------------------ ---------- -------- ----------------- ----------------- ---------- ------------- ----------------------------------------------- ------------------------------
  Chr10:131755589G\>A      Missense   *EBF3*   NM_001005463.2\   NP_001005463.1\   Het        De novo       Deleterious/probably damaging/disease-causing   N/R
                                               c.487C\>T         p.(Arg163Trp)                                                                              

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HGVS, Human Genome Variation Society; SIFT, Sorting Intolerant from Tolerant; ExAC, Exome Aggregation Consortium; N/R, not reported.

Phenotypic Analyses of Patients with *EBF3* Variants {#s2c}
----------------------------------------------------

Comparison of our patient with other recently reported cases with variants affecting the p.Arg163 residue revealed substantial phenotypic overlap ([Table 2](#BLACKBURNMCS001743TB2){ref-type="table"}). All patients had intellectual disability, global developmental delay, speech delay, mild facial dysmorphisms, strabismus, and some urogenital anomaly, such as micropenis, cryptorchidism, urinary retention/reflux, and/or bladder control issues ([Table 2](#BLACKBURNMCS001743TB2){ref-type="table"}). Several structural brain abnormalities were noted in other patients on MRI, but this was not a consistent feature across all patients, including the patient described in this report. Our patient also had several urogenital anomalies including atonic bladder, distal urethral stricture, vesicoureteral reflux, bilateral hydroureter and hydronephrosis, and recurrent urinary tract infections (UTIs). Recurrent UTIs have been described in several other patients, possibly suggestive of underlying urogenital malformations, but only one other patient with a c.512G\>A (p.(Gly171Asp)) variant has been described who had a diagnosis of atonic bladder ([@BLACKBURNMCS001743C19]). Our patient also had a bicornuate uterus, which has not been reported in any other patients with *EBF3* intragenic variants, suggesting that this may represent an additional feature associated with this novel disorder.

###### 

Clinical summary of the patient described in this report and previously reported patients with variants affecting the Arg163 residue

  Variant in EBF3                 Chr10: 131755589G\>A (hg19); NM_001005463.2; c.487C\>T; p.(Arg163Trp)                                                                                                                                                                                                                                           Chr10: 131755588C\>T (hg19); NM_001005463.2; c.488G\>A; p.(Arg163Gln)                                                                                                                                                                                                                      Chr10: 131755588C\>T (hg19); NM_001005463.2; c.488G\>A; p.(Arg163Gln)                                                                                                                                                                                                                      Chr10: 131755588C\>A (hg19); NM_001005463.2; c.488G\>T; p.(Arg163Leu)                                                                                                                                                                                                          Chr10: 131755588C\>G (hg19); NM_001005463.2; c.488G\>C; p.(Arg163Pro)
  ------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                       This report                                                                                                                                                                                                                                                                                                     [@BLACKBURNMCS001743C3]                                                                                                                                                                                                                                                                    [@BLACKBURNMCS001743C3]                                                                                                                                                                                                                                                                    [@BLACKBURNMCS001743C3]                                                                                                                                                                                                                                                        [@BLACKBURNMCS001743C35]
  Inheritance                     De novo                                                                                                                                                                                                                                                                                                         De novo                                                                                                                                                                                                                                                                                    De novo                                                                                                                                                                                                                                                                                    De novo                                                                                                                                                                                                                                                                        De novo
  Sex                             Female                                                                                                                                                                                                                                                                                                          Male                                                                                                                                                                                                                                                                                       Female                                                                                                                                                                                                                                                                                     Female                                                                                                                                                                                                                                                                         Male
  Ethnicity                       Irish, Mexican, German, and French descent                                                                                                                                                                                                                                                                      Pacific Islander of Chinese and Japanese descent                                                                                                                                                                                                                                           African--American                                                                                                                                                                                                                                                                          English, Irish, German, and Polish descent                                                                                                                                                                                                                                     English descent
  Age at most recent assessment   23 mo                                                                                                                                                                                                                                                                                                           7 yr                                                                                                                                                                                                                                                                                       5 yr                                                                                                                                                                                                                                                                                       3 yr                                                                                                                                                                                                                                                                           13 yr
  Birth                           Birth was at term by vaginal delivery and was significant for meconium aspiration and distended bladder requiring catheterization                                                                                                                                                                               Birth was at 38 wk gestation by repeat Caesarean section and was significant for a loose nuchal cord wrapped around the neck and a fractured clavicle                                                                                                                                      Patient\'s prenatal history is significant for decreased fetal movements, and birth was at 40 wk via induced vaginal delivery for oligohydramnios                                                                                                                                          Birth was at 39 wk of gestation by Caesarean section because of breech position                                                                                                                                                                                                Birth was at 38 wk by elective Caesarian section because of breech position
  Birth weight in grams           3490 g                                                                                                                                                                                                                                                                                                          3400 g                                                                                                                                                                                                                                                                                     3350 g                                                                                                                                                                                                                                                                                     2700 g                                                                                                                                                                                                                                                                         3200 g
  Birth length in cm              49.5 cm                                                                                                                                                                                                                                                                                                         52 cm                                                                                                                                                                                                                                                                                      50.8 cm                                                                                                                                                                                                                                                                                    N/R                                                                                                                                                                                                                                                                            N/R
  OFC at birth in cm              N/R                                                                                                                                                                                                                                                                                                             36.2 cm                                                                                                                                                                                                                                                                                    33.5 cm                                                                                                                                                                                                                                                                                    N/R                                                                                                                                                                                                                                                                            N/R
  Weight in kg (percentile)       10.6 kg (30th percentile) at 23 mo                                                                                                                                                                                                                                                                              19.5 kg (25th percentile)                                                                                                                                                                                                                                                                  17.5 kg (41st percentile)                                                                                                                                                                                                                                                                  10th percentile                                                                                                                                                                                                                                                                N/R
  Height in cm (percentile)       71 cm (\<2nd percentile) at 23 mo                                                                                                                                                                                                                                                                               109.7 cm (25th percentile)                                                                                                                                                                                                                                                                 114.8 cm (91st percentile)                                                                                                                                                                                                                                                                 10th percentile                                                                                                                                                                                                                                                                132.5cm (\<1st percentile) at 13 yr
  OFC in cm (percentile)          46.7 cm (30th percentile) at 23 mo                                                                                                                                                                                                                                                                              52.5 cm (50th--75th percentile)                                                                                                                                                                                                                                                            51 cm (85th percentile)                                                                                                                                                                                                                                                                    20th percentile                                                                                                                                                                                                                                                                56.2 cm (50th--75th percentile) at 13 yr
  Intellectual disability         \+                                                                                                                                                                                                                                                                                                              \+                                                                                                                                                                                                                                                                                         \+                                                                                                                                                                                                                                                                                         \+                                                                                                                                                                                                                                                                             \+
  Global developmental                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  delay                           \+                                                                                                                                                                                                                                                                                                              \+                                                                                                                                                                                                                                                                                         \+                                                                                                                                                                                                                                                                                         \+                                                                                                                                                                                                                                                                             \+
  Speech delay                    \+                                                                                                                                                                                                                                                                                                              \+                                                                                                                                                                                                                                                                                         \+                                                                                                                                                                                                                                                                                         \+                                                                                                                                                                                                                                                                             \+
  Hypotonia                       \+                                                                                                                                                                                                                                                                                                              \+                                                                                                                                                                                                                                                                                         \+                                                                                                                                                                                                                                                                                         \+                                                                                                                                                                                                                                                                             \+
  Ataxia                          Not present at time of evaluation                                                                                                                                                                                                                                                                               Gait ataxia                                                                                                                                                                                                                                                                                Gait ataxia, dysmetria                                                                                                                                                                                                                                                                     Gait ataxia                                                                                                                                                                                                                                                                    Gait and truncal ataxia
  Seizures                        N/R                                                                                                                                                                                                                                                                                                             N/R                                                                                                                                                                                                                                                                                        N/R                                                                                                                                                                                                                                                                                        N/R                                                                                                                                                                                                                                                                            N/R
  Brain MRI findings              Brain MRI revealed no abnormalities                                                                                                                                                                                                                                                                             Brain MRI (performed at 7 yr of age) revealed small inferior posterior cerebellar lobes, hypoplasia of the posterior vermis, and mild prominence of the ventricles and sulci                                                                                                               Brain MRI (performed at 18 mo of age) revealed hypoplasia of the anterior and posterior vermis, overfolding of the superior helices, with normal cerebellar hemispheres                                                                                                                    Brain MRI (performed at 1 yr of age) showed normal cerebellar vermis and hemispheres                                                                                                                                                                                           Brain imaging studies (performed at age 1 and 5) revealed cerebellar cleft or absent vermis, cerebellar atrophy, and atrophy of pontine tegmentum
  Facial dysmorphisms             Low posterior hairline, down- turned mouth corners, and mild retrognathia                                                                                                                                                                                                                                       Myopathic facies and short anteverted nostrils                                                                                                                                                                                                                                             Triangular-shaped facies                                                                                                                                                                                                                                                                   Triangular-shaped facies                                                                                                                                                                                                                                                       Dolichocephaly, prominent forehead and occiput, and deep-set eyes
  Strabismus                      Bilateral esotropia                                                                                                                                                                                                                                                                                             \+                                                                                                                                                                                                                                                                                         \+                                                                                                                                                                                                                                                                                         \+                                                                                                                                                                                                                                                                             Esotropia
  Ears                            Ears neutrally set and well formed                                                                                                                                                                                                                                                                              Overfolding of the superior helices                                                                                                                                                                                                                                                        Overfolding of the superior helices                                                                                                                                                                                                                                                        N/R                                                                                                                                                                                                                                                                            N/R
  Urogenital anomalies            Bilateral hydroureter and hydronephrosis after birth due to extreme urinary retention/atonic bladder, vesicoureteral reflux (vesicostomy was performed), distal urethral stricture, recurrent urinary tract infections, bicornate uterus                                                                        Micropenis and cryptorchidism                                                                                                                                                                                                                                                              Mild reduction in volume of the labia majora, lacks bladder control                                                                                                                                                                                                                        Urinary retention associated with incomplete bladder emptying and grade 1 urinary reflux                                                                                                                                                                                       Left cryptorchidism
  Additional clinical findings    Patient has generalized low muscle tone with a normal EMG study with no evidence for myopathy, defect in neuromuscular transmission, or peripheral neuropathy, deep tendon reflexes were decreased (−2/−3 in upper and lower), normal spinal MRI, mild pectus excavatum, uses two to three words purposefully   Clinical features include facial weakness, expressive speech disorder, dysarthria, dysphagia, gastroesophageal reflux disease, and hockey-stick palmar creases                                                                                                                             Patient\'s clinical features include facial weakness, abnormal palmar creases, fifth-finger clinodactyly, expressive speech disorder, apraxia, dysarthria, dysphagia, and perseverative social behaviors. Patient also has marked insensitivity to pain                                    Patient\'s clinical features include facial weakness, expressive speech disorder, dysphagia, motor stereotypies, small feet, and torticollis. Patient speaks only one word, did not walk until late, and has a pincer grasp. Patient also has marked insensitivity to pain     Patient\'s clinical features include pectus excavatum, tapering fingers, pes planus, shortened great toes, dysarthria, and high-pitched voice. The patient stood with support at 2 yr of age, walked independently at 5 yr and 8 mo, has limited speech (50 words), and an IQ of 71.
  Functional evidence             Not done                                                                                                                                                                                                                                                                                                        Activation of COE-binding sequence reporter-gene was assessed in vitro as the ratio of NanoLuc to firefly luciferase. A 92-fold induction was observed with wt EBF3. EBF3 p.Arg163Gln showed a very poor induction of transcription and was indistinguishable from the negative control.   Activation of COE-binding sequence reporter-gene was assessed in vitro as the ratio of NanoLuc to firefly luciferase. A 92-fold induction was observed with wt EBF3. EBF3 p.Arg163Gln showed a very poor induction of transcription and was indistinguishable from the negative control.   Activation of COE-binding sequence reporter-gene was assessed in vitro as the ratio of NanoLuc to firefly luciferase. A 92-fold induction was observed with wt EBF3. EBF3 p.Arg163Leu had only a 45-fold induction, suggesting that the variant is a hypomorphic alteration.   Used μM2.21 cell system to measure the relative transactivation abilities of mutant and wild-type EBF3 proteins across graded levels of expression (assay measures the percentage of surface mIgM expression as a direct readout of EBF3 function). The p.Arg163Pro variant was inactive across all expression levels, suggesting that mutation of this residue ablates EBF3 function.

N/R, not reported; +, present; MRI, magnetic resonance imaging; EMG, electromyography; COE, Collier/Olf/EBF; wt, wild type; EBF3, early B-cell factor 3.

Molecular Modeling and Dynamics Simulations Demonstrate Loss of DNA Binding for p.(Arg163Trp) {#s2d}
---------------------------------------------------------------------------------------------

In this study, we used molecular modeling and physics-based atomic simulation to investigate the effects of p.(Arg163Trp) on DNA binding. Previous work in the EBF3 human paralog EBF1 has demonstrated experimentally that p.Arg163 contacts DNA, intercalating into the minor grove, and that both p.Arg163Trp and p.Arg163Ala lead to loss of DNA binding. Additionally, p.Lys239Ala interacts with DNA, but mutation to alanine had no effect on binding ([@BLACKBURNMCS001743C36]). Thus, we generated triplicate simulation of EBF3 dimers bound to DNA for all four sequence contexts: wt, p.Lys239Ala, p.Arg163Trp, and p.Arg163Ala. Simulations revealed consistent increases in EBF3 dynamics for p.Arg163Ala and p.Arg163Trp, whereas p.Lys239Ala exhibited wt-like behavior ([Fig. 3](#BLACKBURNMCS001743F3){ref-type="fig"}). The increased dynamics is due to loss of DNA contact by the zinc knuckle domain (see [Supplemental Animation 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001743/-/DC1)), which leads to greater deviations from the native conformation ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001743/-/DC1)). To quantify the departure of the zinc knuckle from the DNA minor grove, we measured reference distances between the protein and DNA backbone. These distances are significantly and consistently longer for both p.Arg163 variants (see [Fig. 3](#BLACKBURNMCS001743F3){ref-type="fig"}; [Supplemental Fig. S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001743/-/DC1)), whereas the wt and p.Lys239Ala remain stable. MD simulations capture both the short-scale random atomic fluctuations and the large-scale motions of the protein. We applied principal component (PC) analysis to our simulation data to identify the large-scale motions therein. We summarized these large-scale motions of EBF3, revealing that loss of contact between the zinc knuckle and DNA leads to large-scale conformations changes characterized by pivoting of EBF3 around the DNA helix axis ([Supplemental Fig. S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001743/-/DC1)). Thus, atomic simulations of EBF3 variants agree with biochemical experiments performed for EBF1 and indicate that p.(Arg163Trp) is likely to lead to loss of DNA affinity.

![p.Arg163Trp induces dynamic changes throughout EBF3 that are comparable to the validated pathogenic p.Arg163Ala and distinct from control simulations. (*A*) We calculated the average root-mean-square deviation (RMSD) across replicates for each simulation condition (indicated by color). Proteins with alterations at residue 163 demonstrated increased mobility throughout both monomers (indicated by light and dark gray rectangles along the abscissa) with the greatest differences among the DNA-interacting regions (black rectangles) around p.Arg163. (*B*) To quantify the differences between conformations, we measured the distance from residue 163 (violet sphere) to nearby phosphate atoms in the DNA backbone (orange spheres). (*C*) We show a comparison using one of these reference distances (larger sphere in *B*), demonstrating that both the wild-type (wt) and p.Lys239Ala retain stable DNA interactions, whereas both p.Arg163Ala and p.Arg163Trp lose contact with DNA. Additional distance measures are presented in [Supplemental Figure S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001743/-/DC1).](BlackburnMCS001743_F3){#BLACKBURNMCS001743F3}

DISCUSSION {#s3}
==========

EBF3 is one of four highly related transcription factors in the COE family found in humans. EBF3 is composed of an amino-terminal DBD, an Ig-like/plexins/transcription factors (IPT) domain, a helix--loop--helix (HLH) domain, and a carboxy-terminal domain ([Fig. 2](#BLACKBURNMCS001743F2){ref-type="fig"}; [@BLACKBURNMCS001743C26]). The DBD coordinates a zinc ion through a histidine and three cysteine residues that form a 14-residue zinc knuckle motif that is essential for DNA binding ([@BLACKBURNMCS001743C17]; [@BLACKBURNMCS001743C26]). In humans, there is 97% homology at the amino acid level between EBF1 and EBF3 within the DBD, which suggests that these related proteins have similar DNA-binding properties ([@BLACKBURNMCS001743C8]). In this report, we describe a patient with a novel p.(Arg163Trp) missense mutation that falls within a highly conserved residue in the zinc knuckle motif. Molecular modeling as well as functional confirmation in patients (see [Table 2](#BLACKBURNMCS001743TB2){ref-type="table"} for description of functional studies performed) with other variants affecting the p.Arg163 residue, strongly suggest that the variant found in our patient is pathogenic. In addition, our patient showed extensive phenotypic overlap with recently reported patients ([@BLACKBURNMCS001743C3]; [@BLACKBURNMCS001743C19]; [@BLACKBURNMCS001743C35]). Our patient had several urogenital abnormalities, including a bicornuate uterus, which has not been described in any other patients to date and may represent an expansion of the known phenotype.

EBF3 has been less well studied than other EBF family members, but is known to be expressed in early post-mitotic neurons during development and plays a role in neurogenesis ([@BLACKBURNMCS001743C12]). In invertebrate model organisms, the *EBF3* orthologs *collier* in *Drosophila melanogaster* and *unc-3* (CeO/E) in *Caenorhabditis elegans* are expressed in mandibular and intercalary segment primordia during head specification in flies ([@BLACKBURNMCS001743C6]; [@BLACKBURNMCS001743C7]) as well as in chemosensory and developing motor neurons during axonal outgrowth in worms ([@BLACKBURNMCS001743C32]). Studies in *Xenopus* revealed that EBF3 ortholog (Xebf3) is activated by XNeuroD and is expressed in primary neurons where it regulates neuronal differentiation ([@BLACKBURNMCS001743C31]). At the transcriptional level in *Xenopus, xebf2 and xebf3* appear to have largely overlapping patterns of expression and may have partially redundant functions ([@BLACKBURNMCS001743C15]). This appears to be supported by the fact that *Ebf2* and *Ebf3* knockout mice as well as *Ebf2/3* double heterozygous knockout mice have similar phenotypes with defects in neuronal development and olfactory axon growth ([@BLACKBURNMCS001743C37]). In mice, *Ebf3* is also expressed in Cajal--Retzius (CR) cells, which are important for the development of the cerebral cortex ([@BLACKBURNMCS001743C4]). Together, *Ebf2* and *Ebf3* appear to regulate the migration of CR cells arising in the cortical hem during corticogenesis, and disruption of these genes leads to defects in neuronal development ([@BLACKBURNMCS001743C4]).

Gene expression profiling comparing *Arx* mutant and E14.5 wild-type ventral telencephalic tissues in mice revealed that *Ebf3* is one of the most differentially expressed genes in *Arx* mutant ganglionic eminences where it is not typically expressed ([@BLACKBURNMCS001743C5]). *Arx* encodes the Aristaless-related homeobox protein, which is an essential transcription factor involved in patterning, neuronal proliferation and differentiation, and axonal outgrowth ([@BLACKBURNMCS001743C11]). *Arx* has been shown to be sufficient to repress *Ebf3* expression, and defects in neuronal development in *Arx* mutant mice can be partially rescued through *Ebf3* silencing ([@BLACKBURNMCS001743C5]). Interestingly, pathogenic variants in *ARX* result in a number of developmental disorders in humans including lissencephaly (LISX2; MIM\# 300215), Proud syndrome (MIM\# 300004), infantile spasms without brain malformations (EIEE1; MIM\# 308350), and syndromic (MIM\# 309510) and nonsyndromic (MIM\# 300419) mental retardation ([@BLACKBURNMCS001743C11]). Patients with *ARX*-related disorders that have CNS malformations can also present with urogenital anomalies, suggesting that the expression patterns of *EBF3* and *ARX* are both antagonistic and tightly regulated in a number of different tissues ([@BLACKBURNMCS001743C11]). Prior to recent reports, EBF3 had not been implicated definitively in any disorder in humans. However, patients with 10q26 microdeletion syndrome that includes a 3.5 Mb minimally deleted region (SROII) involving *EBF3* have several overlapping clinical features with individuals carrying *EBF3* intragenic variants, including short stature, craniofacial dysmorphisms, strabismus, abnormal ears, genital anomalies, urinary tract anomalies, CNS malformations, microcephaly, and intellectual disability ([@BLACKBURNMCS001743C9]). As in ARX-related disorders, variants in *EBF3* are associated with marked phenotypic and clinical heterogeneity, with some patients presenting with structural brain abnormalities and others having no evidence of CNS malformations.

EBF3 Is Expressed in Skeletal Muscle and Is Involved in Muscle Development and Muscle-Specific Transcription {#s3a}
------------------------------------------------------------------------------------------------------------

Outside of the CNS, *Ebf3* shows the highest expression levels in the diaphragm, bone marrow, and skeletal muscle in developing mouse embryos ([@BLACKBURNMCS001743C22]). Adult mice express *Ebf3* at the highest levels in skeletal muscle, the uterus, the eye, and the diaphragm ([@BLACKBURNMCS001743C22]). In *Drosophila*, *collier* is expressed in muscle progenitors and is required for myoblast fusion ([@BLACKBURNMCS001743C7]). Similarly in *Xenopus, Ebf2* and *Ebf3* are expressed in muscle and are required for somite organization, migration of hypaxial muscle anlagen, and the development of jaw muscle ([@BLACKBURNMCS001743C16]). *MyoD* and *Myf5* appear to be direct targets of these transcription factors ([@BLACKBURNMCS001743C16]). MyoD can also up-regulate the expression of *Ebf* genes, suggestive of a positive feedback loop between Ebf and MyoD that is necessary for differentiation of muscle cells in *Xenopus* ([@BLACKBURNMCS001743C16])*. Ebf3* knockout mice die of respiratory failure before postnatal day 2 because of failure of the lung to unfold ([@BLACKBURNMCS001743C22])*.* This lethal phenotype is caused by a hypercontractile diaphragm with impaired Ca^2+^ efflux due to down-regulation of *Serca1 (Atp2a1)* in the absence of *Ebf3* ([@BLACKBURNMCS001743C22])*.* EBF3 has been shown to bind to the promoter of *Atp2a1* and synergizes with MYOD to induce expression of other muscle-specific target genes ([@BLACKBURNMCS001743C22]). *Ebf3* is also expressed in the urogenital tract of developing mice, including regions that correspond to the detrusor muscle of the bladder and the muscle layer of the pelvic urethra ([Supplemental Fig. S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001743/-/DC1)) ([@BLACKBURNMCS001743C29]; [@BLACKBURNMCS001743C18]). Given its role in muscle development and contraction, it is possible that disruption of EBF3-mediated transcription in muscle could lead to hypotonia, atonic bladder/loss of bladder control, and other phenotypes observed in patients with pathogenic *EBF3* variants. Further studies will be essential to unraveling the role of EBF3 in the expression of disease in humans.

METHODS {#s4}
=======

Sample Collection and WES {#s4a}
-------------------------

Whole-exome sequencing was performed on genomic DNA extracted from all samples submitted. The exome was captured utilizing a custom reagent developed by the Mayo Clinic and Agilent Technologies, targeting 19,456 genes and 187,715 exons using 637,923 probes to capture a 54.1 Mbp total region. Sequencing was performed on an Illumina HiSeq 2500 Next-Generation sequencing instrument, using HapMap Sample NA12878 as an internal control. Paired-end 101-bp reads were aligned to a modified human reference genome (GRCh37/hg19) using Novoalign (Novocraft Technologies). Sequencing quality was evaluated using FastQC ([www.bioinformatics.babraham.ac.uk/projects/fastqc/](www.bioinformatics.babraham.ac.uk/projects/fastqc/)). All germline variants were jointly called through GATK Haplotype Caller and GenotypeGVCF ([@BLACKBURNMCS001743C28]). Each variant was annotated using the BioR Toolkit ([@BLACKBURNMCS001743C23]) and subsequently evaluated for clinical relevance. Sequencing results are shown in [Table 3](#BLACKBURNMCS001743TB3){ref-type="table"}.

###### 

Sequencing summary

  10× Coverage   Mean coverage   Yield (Gb)   \>Q30 (%)   Mean Q   Filtered variants   *EBF3* mean exon coverage   Variant coverage
  -------------- --------------- ------------ ----------- -------- ------------------- --------------------------- ------------------
  98.63%         140×            15.3         99.92       38.405   75117               72×                         379

Q30, quality score of 30; EBF3, early B-cell factor 3.

Molecular Modeling and Molecular Dynamics Simulations {#s4b}
-----------------------------------------------------

Our modeling and analysis began from the UniProt sequence of EBF3 (also known as COE3), Q9H4W6, which is 97% identical to EBF1 across its DNA binding domain ([@BLACKBURNMCS001743C13]). The initial configuration of our structure was generated using homology modeling from the crystal structure of EBF1 dimer bound to DNA, 3MLP ([@BLACKBURNMCS001743C36]), using Modeller ([@BLACKBURNMCS001743C27]) and an automated modeling approach ([@BLACKBURNMCS001743C38]). All-atom implicit environment configurations were generated using VMD ([@BLACKBURNMCS001743C21]). Molecular dynamics (MD) simulations were carried out using NAMD ([@BLACKBURNMCS001743C30]) and the CHARMM36 force field ([@BLACKBURNMCS001743C2]; [@BLACKBURNMCS001743C20]). Triplicate simulations for each variant were independently energy minimized for 10,000 steps, followed by heating to 300 K over 600 ps via a Langevin thermostat and equilibration for 1ns, with a simulation time step of 1fs and conformations recorded every 2 ps. A further 5 ns of simulation trajectory was generated for analysis. Prior to analysis, all trajectories were aligned to the initial wt conformation using DNA backbone atoms. Principal component (PC) analysis was performed in Cartesian space on protein C^α^ atoms. Analysis was carried out using custom scripts, leveraging VMD and the Bio3D R package ([@BLACKBURNMCS001743C14]). Protein structure visualization was performed in PyMOL version 1.7.6. ([@BLACKBURNMCS001743C33]) and VMD v1.9.3.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5b}
--------------------------

Whole-exome sequencing data is not publicly available because patient consent could not be obtained. The variant has been submitted to ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) under accession number SCV000493129.
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